DELIVER: Extending the benefits of SGLT-2 inhibitors

Kerollos Samaan; Kerolos Wagdy

doi:10.21542/gcsp.2023.21

DELIVER: Extending the benefits of SGLT-2 inhibitors

Glob Cardiol Sci Pract. 2023 Aug 1;2023(3):e202321. doi: 10.21542/gcsp.2023.21.

Authors

Kerollos Samaan^{1

2}, Kerolos Wagdy¹

Affiliations

¹ Cardiology Department, Aswan Heart Centre, Aswan, Egypt.
² Cardiology Department, Cairo University, Cairo, Egypt.

Abstract

The DELIVER trial investigated the efficacy and safety of dapagliflozin in patients with heart failure and preserved or mildly reduced ejection fraction. The trial demonstrated that dapagliflozin significantly reduced the risk of worsening heart failure or cardiovascular death compared to placebo. The benefit was mainly driven by a decrease in heart failure hospitalizations, with no significant impact on mortality. Patients with different ejection fractions and diabetes status showed similar treatment effects. Dapagliflozin also improved functional capacity and quality of life. These findings support the use of SGLT-2 inhibitors in HFpEF and HFmrEF, potentially influencing clinical practice and future guidelines.